Jennifer Tousignant

CIK: 0002010978

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (27.3%)

Position reduction

Option Exercises (M)2 (18.2%)

Derivative conversions

Awards (A)4 (36.4%)

Compensation grants

Other (G, F, J, C, D, …)2 (18.2%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

$Viridian Therapeutics, Inc.\DE logo$

VRDN

Viridian Therapeutics, Inc.\DE

Officer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Aug 19, 2026
Sale(S)
Direct
10K shares at avg. $24.50$245K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Aug 19, 2026
Sale(S)
Direct
4.2K shares at avg. $24.50$103K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Aug 19, 2026
Exercise(M)
Direct
10K shares at avg. $14.41$144K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Tax Payment(F)
Direct
1.7K shares at avg. $30.19$51K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Exercise(M)
Direct
5.2K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2026
Tax Payment(F)
Direct
1.7K shares at avg. $29.32$51K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
119.3K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 2, 2026
Award(A)
Restricted Stock Units
Direct
23.9K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Dec 31, 2025
Sale(S)
Direct
2.3K shares at avg. $31.16$71K
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
124.1K shares-
$Viridian Therapeutics, Inc.\DE logo$
VRDN
Viridian Therapeutics, Inc.\DE
Mar 3, 2025
Award(A)
Restricted Stock Units
Direct
20.7K shares-

		Type	Shares	Price		Ownership
Aug 19, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Sale(S)	10,000	$24.50	$245,000	Direct
Aug 19, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Sale(S)	4,212	$24.50	$103,194	Direct
Aug 19, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Exercise(M)	10,000	$14.41	$144,100	Direct
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Tax Payment(F)	1,675	$30.19	$50,568	Direct
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Exercise(M)	5,169	-	$0	Direct
Mar 3, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Tax Payment(F)	1,724	$29.32	$50,548	Direct
Mar 2, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Stock Option (Right to Buy)	119,300	-	-	Direct
Mar 2, 2026	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Restricted Stock Units	23,850	-	-	Direct
Dec 31, 2025	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Sale(S)	2,272	$31.16	$70,796	Direct
Mar 3, 2025	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Stock Option (Right to Buy)	124,072	-	-	Direct
Mar 3, 2025	$Viridian Therapeutics, Inc.\DE logo$ VRDN Viridian Therapeutics, Inc.\DE	Award(A) Restricted Stock Units	20,679	-	-	Direct

1-11 of 11 transactions

About Tousignant Jennifer

Tousignant Jennifer (SEC CIK 0002010978) files insider reports with the SEC as Chief Legal Officer of Viridian Therapeutics, Inc.\DE (VRDN).

Signal8 holds 6 ownership filings by Tousignant Jennifer, all Form 4s, filed between Mar 4, 2025 and Aug 20, 2026. Those filings report 11 transactions, from Mar 3, 2025 to Aug 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Tousignant Jennifer's filings is in WALTHAM, MA.

Recent filings by Tousignant Jennifer

Aug 19, 2026: Open-market sales of VRDN shares (2 lines, Form 4, code S).
Aug 19, 2026: Option exercise of VRDN shares (Form 4, code M).
Mar 3, 2026: Tax withholding of VRDN shares (Form 4, code F).
Mar 3, 2026: Option exercise of VRDN shares (Form 4, code M).
Mar 3, 2026: Tax withholding of VRDN shares (Form 4, code F).

Other insiders filing for Viridian Therapeutics, Inc.\DE (VRDN)

Tripuraneni Radhika, Chief Medical Officer
CAIN CHRISTOPHER W., Director
Ajer Jeffrey Robert, Director
Moses Jennifer K., Director
Gheuens Sarah, Director
Kiselak Tomas, Director

How to read Form 4 transaction codes